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allow this issue to be resolved in the fu-
ture. The findings of Mitro et al. (2007),
if confirmed to be physiologically rele-
vant, may lead to new directions in the
hunt for novel therapeutics that ame-
liorate disorders of glucose and lipid
metabolism. More broadly, these re-
sults should push us to further define
the requirements that distinguish phe-
nomenology from physiology when
evaluating naturally occurring ligands
as potential hormones.
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Obesity-associated, system-wide elevations in free fatty acids, tumor necrosis factor a, and
glucocorticoids increase intracellular lipid metabolites and promote insulin resistance. In this issue,
Holland et al. (2007) provide pharmacological and genetic evidence that ceramide plays a key role in
the development of insulin resistance induced by these factors.The modern ‘‘super-size me’’ society
offers an abundance of high-energy
foods that are fueling the fires of
obesity-induced insulin resistance.
Obesity is now recognized as one of
the predisposing factors for the devel-
opment of insulin resistance in skeletal
muscle and liver and a major contribu-
tor to the worldwide escalation in the
incidence of non-insulin-dependent
(type 2) diabetes mellitus. Cushing’s
syndrome is a rare disorder caused
by systemic glucocorticoid excess
that shares many metabolic and mor-
phological similarities with obesity,
including insulin resistance, visceral
obesity, hypertension, and dyslipide-
mia. The overlapping phenotype be-
tween clinical profiles associated withobesity and Cushing’s syndrome rai-
ses the possibility of a common mo-
lecular mechanism for disease onset.
Given the disease burden and health
costs associated with the rising
prevalence of obesity and common
morbidities such as type 2 diabetes,
hypertension, cardiac failure, and ath-
erosclerosis, efforts to identify and val-
idate mechanisms for the cause and
cure of metabolic disorders are war-
ranted. Emerging evidence suggests
that nutrient excess is associated
with an increase in specific lipid-
derivedmetabolites that inactivate sig-
naling intermediates and cause insulin
resistance. However, the mechanism
by which specific lipid metabolites
cause insulin resistance is incom-Cell Metabolismpletely resolved. In this issue of Cell
Metabolism, Summers and colleagues
(Holland et al., 2007) identify the sphin-
golipid metabolite ceramide as a com-
mon molecular intermediate linking
excess nutrients (i.e., saturated fatty
acids, but not unsaturated fats) and
glucocorticoids to the induction of
insulin resistance.
Several mechanisms have been
proposed to explain how increased
adipose mass affects whole-body in-
sulin sensitivity. One theory is that
adipose-tissue-derived cytokines in-
duce a chronic inflammatory state that
antagonizes insulin signaling and mi-
tochondria function, thereby impair-
ing glucose homeostasis (Hotamisligil,
2006). Another popular theory is based5, March 2007 ª2007 Elsevier Inc. 161
Cell Metabolism
PreviewsFigure 1. Proposed Mechanism of Ceramide Action on Insulin Signaling and
Metabolism
Increased adipose mass leads to an increase in systemic levels of free fatty acids (FFA), tumor
necrosis factor a (TNFa), and glucocorticoids that stimulates the accumulation of ceramides in
a variety of tissues. Ceramide activates protein phosphatase 2A (PP2A) and inhibits Akt/PKB
activity and translocation. Inhibition of insulin signaling impairs glucose uptake in skeletal muscle
and insulin repression of glucose efflux in liver.on evidence that excessive accumula-
tion of lipid molecules in nonadipose
tissues that are not suited for fat stor-
age leads to the buildup of metabolites
that stimulate negative feedback path-
ways to inhibit insulin signaling and
metabolism (McGarry, 2002). These
mechanisms likely contribute to the
downregulation of insulin signaling in
peripheral tissues. Excessive levels of
free fatty acids (FFAs), tumor necrosis
factor a (TNFa), and glucocorticoids,
through different mechanisms, stimu-
late the accumulation of the sphingoli-
pid ceramide and various ceramide
metabolites (Summers and Nelson,
2005). Conversely, exercise training,
which also improves insulin sensitivity,
is associated with depletion of skele-
tal muscle ceramide (Dobrzyn and
Gorski, 2002).
Ceramide synthesis is dependent on
the availability of long-chain saturated
fats, which participate in the initial
rate-limiting reaction involving the
condensation of palmitoyl-CoA and
serine, by a reaction catalyzed by
serine palmitoyltransferase (SPT) to
produce 3-oxosphinganine (Hannun,
1994). The availability of palmitoyl-
CoA and serine strongly influences
the rate of this reaction. Subsequent162 Cell Metabolism 5, March 2007 ª200reactions lead to the sequential syn-
thesis of sphinganine, dihydrocera-
mide, and ceramide, with the latter
acting as a precursor of most active
sphingolipids (Mathias et al., 1998).
The synthesis of biologically active
ceramide is completed by dihydrocer-
amide desaturase (DES1). Although
ceramides are one of the component
lipids that make up sphingomyelin,
a major lipid in the lipid bilayer, they
also play an important role as an intra-
cellular signaling molecule. Increased
ceramide synthesis in response to
excessive TNFa, saturated FFAs, or
glucocorticoids is associated with an
inhibition of insulin signal transduction
by inhibiting Akt/PKB phosphorylation
and activation (Figure 1). Ceramide
promotes the dephosphorylation of
Akt/PKB by protein phosphatase 2A
(PP2A) (Dobrowsky et al., 1993) and
blocks the translocation of Akt/PKB
from the cytoplasm to the plasma
membrane (Stratford et al., 2004).
Holland et al. (2007) used pharma-
cological agents and genetically mod-
ified animals to test whether inhibition
of ceramide synthesis improves glu-
cose homeostasis in rodent models
of insulin resistance, obesity, and dia-
betes. They report that myriocin, an7 Elsevier Inc.antifungal compound that inhibits
SPT, improves glucose tolerance in
glucocorticoid-treated rats. Myriocin
pretreatment partially maintained skel-
etal muscle insulin sensitivity and
completely preserved hepatic insulin
sensitivity in vivo, coincident with im-
proved insulin action at the level of
Akt/PKB. Treatment also lowered cer-
amide levels and prevented the pro-
gressive development of metabolic
abnormalities in Zucker diabetic fatty
rats. Myriocin failed to prevent lipid
induction of inflammatory cytokines,
indicating that the compound works
independently or downstream of in-
flammatory modulators. From these
pharmacological studies, the authors
conclude that ceramide inactivation
of Akt/PKB is a contributing mecha-
nism by which the sphingolipid im-
pairs insulin action. Future studies in
which Akt/PKB signaling is genetically
perturbed should be able to more def-
initely address its role in ceramide-
mediated insulin resistance in skeletal
muscle or liver.
Using a more direct approach to
target key enzymes in the ceramide
synthesis pathway, the authors used
DES1 knockout mice to address
whether specifically targeting this
enzyme, which converts metabolically
inactive dihydroceramide into active
ceramide in most peripheral tissues,
modifies insulin sensitivity. Des1 null
mice were runted and sickly, highlight-
ing the importance of ceramides in
normal physiology. Importantly, partial
reduction of the DES1 enzyme in het-
erozygous knockout mice reduced
the ratio of active ceramide to inactive
dihydroceramide and lowered sphin-
golipid levels. The Des1 haploinsuffi-
cient mice exhibited enhanced insu-
lin sensitivity and protection against
dexamethasone-induced insulin resis-
tance. Despite the caveats associated
with the null phenotype, this work val-
idates DES1 as a potential therapeutic
target for the prevention of insulin re-
sistance caused by nutrient excess or
glucocorticoid therapy.
While lipid metabolites are gaining
recognition as signal transducers,
there is a growing appreciation that
not all fats are alike. Unsaturated fats,
derived from plants, are considered
‘‘healthy,’’ whereas saturated fats,
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considered ‘‘unhealthy.’’ Conse-
quently, the lipid metabolites derived
from these different forms of fat may
play specialized roles as signal trans-
ducers. Holland et al. (2007) highlight
a dichotomy between themechanisms
bywhich saturated versus unsaturated
fats cause insulin resistance. Satu-
rated fats induce insulin resistance
through a ceramide-dependent path-
way; unsaturated fats do so through
other lipid intermediates such as fatty
acyl-CoAs and diacylglycerol. While
ceramide-dependent mechanisms ap-
pear to contribute to the development
of insulin resistance induced by satu-
rated fats, the contribution of ceram-
ide-independent metabolites to the
insulin-resistance phenotype cannot
be completely excluded. For example,
diacylglycerides have been implicated
in the development of insulin resis-
tance (Turinsky et al., 1990) via activa-
tion of protein kinase C isoforms and
negative feedback on the insulin sig-
naling cascade (Itani et al., 2002).
These observations highlight diacyl-
glycerol as an attractive candidate for
peripheral insulin resistance since
levels of this lipid metabolite are in-
creased during lipid infusions and fat
feeding. These findings warrant future
studies to unravel the relative contri-bution of excessive ceramide versus
diacylglyceride content to the insulin-
resistance phenotype in humans.
Part of the metabolic mystery of the
deleterious effects of saturated fats
and excessive glucocorticoids on in-
sulin sensitivity may be explained by
an accumulation of ceramide and im-
pairments of insulin signaling. Future
efforts to validate the role of cer-
amide-induced insulin resistance will
require pharmacological approaches
that offer greater specificity in modu-
lating DES1 or other key regulators in
the ceramide biosynthesis pathway,
such as SP1 or dihydroceramide syn-
thase. Genetic studies in humans to
ascertain whether obesity-induced in-
sulin resistance can be attributed to
polymorphisms in the ceramide syn-
thesis pathway may reveal the clinical
importance of this pathway in human
disease. For example, are functional
single-nucleotide polymorphisms
(SNPs) present in key enzymes of this
pathway, and if so, do they render an
individual more sensitive or resistant
to the accumulation of ceramides and
the ensuing effect of this lipid metab-
olite on insulin sensitivity? Finally,
whether these results can be trans-
lated from bench to bedside to treat
obesity- or glucocorticoid-induced
insulin resistance in humans remainsCell Metabolisman open question. Nonetheless, Hol-
land et al. (2007) have shown that
targeting the ceramide biosynthesis
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